BioCentury
ARTICLE | Clinical News

SMT 19969: Phase I data

April 29, 2013 7:00 AM UTC

A double-blind, placebo-controlled Phase I trial in 56 healthy male volunteers showed that single doses of SMT 19969 and twice-daily doses of SMT 19969 for 10 days were well tolerated. Additionally, S...